Production (Stage)
NervGen Pharma Corp.
NGENF
$2.42
$0.19558.81%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 27.05% | -22.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.50% | -7.34% | |||
| Operating Income | 13.50% | 7.34% | |||
| Income Before Tax | 55.27% | -60.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 55.27% | -60.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 55.27% | -60.51% | |||
| EBIT | 13.50% | 7.34% | |||
| EBITDA | 13.50% | 7.37% | |||
| EPS Basic | 55.75% | -60.69% | |||
| Normalized Basic EPS | 55.74% | -60.53% | |||
| EPS Diluted | 55.75% | -60.69% | |||
| Normalized Diluted EPS | 55.74% | -60.53% | |||
| Average Basic Shares Outstanding | 0.97% | -0.12% | |||
| Average Diluted Shares Outstanding | 0.97% | -0.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||